Bedi G, Redman J (2006) Self-reported ecstasy use: the impact of assessment method on dosage estimates in recreational users. J Psychopharmacol (in press)
2.
Colado M I, Camarero J, Mechan A O, Sanchez V, Esteban B, Elliott J M, Green A R (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) on dopamine neurons in mouse brain. Br J Pharmacol134: 1711–1723
3.
Cole J C, Bailey M, Sumnall H R, Wagstaff G F, King L A (2002) The contents of ecstasy tablets: implications for the study of their long-term effects. Addiction97: 1531–1536
4.
Curran V (2000) Is MDMA (‘Ecstasy’) neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology42: 34–41
5.
Curran H V, Robjant K (2006) Eating attitudes, weight concerns and beliefs about drug effects in women who use ecstasy. J Psychopharmacol (in press)
6.
Daumann J, Till B, Fischermann T, Rezk M, Gouzoulis-Mayfrank E (2006) Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study. J Psychopharmacol20: 235–243
7.
Dumont G J H, Verkes R J (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol20: 175–186
8.
Easton N, Marsden C (2006) Ecstasy: are data consistent between species and can they translate to humans?J Psychopharmacol20: 193–209
9.
Fone K C F, Beckett S R G, Topham I A, Swettenham J, Ball M, Maddocks L (2002) Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology159: 437–444
10.
Fox H, Parrott A C, Turner J J D (2001) Ecstasy/MDMA related cognitive deficits: a function of dosage rather than awareness of problems. J Psychopharmacol15: 273–281
11.
Gouzoulis-Mayfrank E, Daumann J (2006) The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol20: 187–192
12.
Guillot C, Greenway D (2006) Recreational Ecstasy use and depression. J Psychopharmacol (in press)
13.
Hoshi R, Pratt H, Mehta S, Bond A J, Curran H V (2006) An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood – are there gender differences?J Psychopharmacol20: 290–300
14.
Huxster J K, Pirona A, Morgan M J (2006) The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans. J Psychopharmacol20: 280–289
15.
Krystal J H, Price L H, Opsahl C, Ricaurte G A, Heninger G R (1992) Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?Am J Drug & Alc Abuse18: 331–341
16.
Lamers C T J, Bechara A, Rizzo M, Ramaekers J G (2006) Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. J Psychopharmacol20: 301–310
17.
McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A (1998) Positron emission tomographic evidence of toxic effect of MDMA (‘Ecstasy’) on brain serotonin neurones in human beings. Lancet352: 1433–1437
18.
McCann U D, Eligulashvili V, Ricaurte G A (2000) 3,4 methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology42: 11–16
19.
Morley K C, Gallate J E, Hunt G E, Mallett P E, McGregor I S (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methlenedioxymethamphetamine (‘Ecstasy’). Eur J Pharmacol433: 91–99.
20.
Murphy P N, Wareing M, Fisk J E (2006) Users’ perceptions of the risks and effects of taking ‘ecstasy’ (MDMA): a questionnaire study. J Psychopharmacol (in press)
21.
Parrott A C (2000) Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology42: 17–24
22.
Parrott A C (2004). Is Ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology173: 234–241.
23.
Parrott A C (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol20: 146–162
24.
Parrott A, Morinan A, Moss M, Scholey A (2004) Understanding Drugs and Behaviour. Wiley, Chichester
25.
Quednow B B, Jessen F, Kühn K-U, Maier W, Daum I, Wagner M (2006) Memory deficits in abstinent MDMA (‘Ecstasy’) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol (in press)
26.
Reay J L, Hamilton C, Kennedy D O, Scholey A B (2006) MDMA polydrug users show process specific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharmacol (in press)
27.
Reneman L, de Win M M L, van den Brink W, Booij J, den Heeten G J (2006a) Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol20: 163–174
28.
Reneman L, Schilt T, de Win M M, Booij J, Schmand B, van den Brink W, Bakker O (2006b) Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharmacol (in press)
29.
Ricaurte G A, Yuan J, McCann U D (2000). (±)3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology42: 5–10
30.
Rodgers J, Buchanan T, Pearson C, Parrott A C, Ling J, Heffernan T, Scholey A B (2006) Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an interent study. J Psychopharmacol (in press)
31.
Schifano F (2000) Potential human neurotoxicity of MDMA (‘Ecstasy’) subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology42: 25–33
32.
Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse A H (2006) Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003). J Psychopharmacol (in press)
33.
Semple D M, Ebmeier K P, Glabus M F, O'Carroll R E, Johnstone E C (1999) Reduced in vivo binding to serotonin transporters in the cerebral cortex of MDMA (‘Ecstasy’) users. Br J Psych175: 63–69.
34.
Soar K, Turner J J D, Parrott A C (2006) Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and preexisting psychiatric factors. J Psychopharmacol (in press)
35.
Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol20: 210–224
36.
de Win M M L, Schilt T, Reneman L, Vervaeke H, Jager G, Dijkink S, Booij J, van den Brink W (2006) Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. J Psychopharmacol20: 225–234
37.
Wolff K, Tsapakis E M, Winstock A R, Hartley D, Holt D, Forsling M L, Aitchison K J (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol (in press)
